Regulation

Massachusetts Sets 60-To-72-Hour Window For Cannabis Mold Tests

mm
Add MyCannabis.com to your preferred sources on Google
Key PointsMassachusetts now requires cannabis yeast and mold tests to incubate within a…
View more
  • Massachusetts now requires cannabis yeast and mold tests to incubate within a 60-to-72-hour window.
  • The commission treats that window as its own expectation rather than a universal USP requirement.
  • Results from unvalidated methods may be deemed invalid and expose laboratories to administrative action.

The Massachusetts Cannabis Control Commission’s Investigations and Enforcement Department on November 13, 2026 issued an immediately effective compliance bulletin directing independent testing laboratories to incubate and enumerate culture-based yeast and mold tests within 60 to 72 hours. The bulletin also requires each microbiological method to be suitable for the matrix being tested and performed according to validated sample-preparation and sample-size procedures.

Any laboratory whose current method or validation does not support that window must resolve the discrepancy through appropriate method validation or other action demonstrating suitability before applying the method under the requirement.

The commission characterized the incubation window as its own expectation, not a universal requirement prescribed by the United States Pharmacopeia or an identical finding across all published validation studies. Its review illustrates the distinction: CompactDry YMR was evaluated under conditions including 72 hours, while the 3M Petrifilm Yeast and Mold Count Plate was evaluated with five-day incubation.

USP Framework And Cannabis-Specific Evidence

Section 7.4 of the commission’s Sampling and Analysis Protocol requires methods for enumerating and identifying specific microbiological contaminants to be consistent with United States Pharmacopeia Chapters 61 and 62. The bulletin applies that framework to cannabis testing by emphasizing suitability confirmation when a change in testing performance or in the product may affect the outcome. Laboratories must follow the validated method’s preparation, sample-size, incubation and enumeration procedures.

The cannabis-specific validation background includes AOAC INTERNATIONAL’s work. In June 2021, the organization announced Performance Tested Methods status for six yeast-and-mold test kits used with dried cannabis flower under its Emergency Response Validation process. Most had previously been validated for various food products. The Performance Tested Methods evaluation procedure includes independent testing at an AOAC Research Institute-recognized laboratory.

A 2023 matrix-extension paper for AOAC Official Method 2014.05 shows why the result depends on both method and matrix. Researchers compared the 3M Petrifilm Rapid Yeast and Mold Count Plate with dichloran rose bengal chloramphenicol agar, the reference method, using naturally contaminated dried cannabis flower at low, medium and high contamination levels. The authors reported equivalent average log counts under the evaluated 60- and 72-hour conditions. The study addressed analytical performance in dried flower, not a universal incubation period for every culture-based method or cannabis product matrix.

Sample Size And Documentation Requirements

Validated methods must specify the sample size to be tested. Laboratories using a published reference method must use its stated size unless an alternative has been appropriately validated. An alternative requires a validation study demonstrating equivalent and suitable results for the intended application and matrix. Convenience, routine practice or an assumption that the change will not affect the outcome is insufficient.

Official Method 2014.05 provides a method-specific example. For dried cannabis flower with THC above 0.3%, it specifies a 10-gram sample diluted with 90 milliliters of sterile 0.1% peptone water. Those instructions do not establish a universal sample size for every microbiological method.

Laboratories must follow validated methods for every sample, consistent with their standard operating procedures and ISO 17025:2017. Testing records must demonstrate compliance with the applicable method and the bulletin, including consistent implementation for all applicable samples. Results obtained with an unvalidated method may be deemed invalid. Results from noncompliant laboratories may also face further scrutiny, and the commission may take administrative action to protect public health, safety and welfare.

For Massachusetts licensees, the bulletin ties the regulatory validity of each applicable yeast-and-mold result to the validation record behind it. The matrix, sample size and incubation documentation therefore matter alongside the reported count, because weaknesses in any of them can expose both the result and the laboratory’s practices to commission scrutiny.

Citation: Schumacher, April, Cari Lingle, and Karen M. Silbernagel. “3M Petrifilm Rapid Yeast and Mold Count Plate for the Enumeration of Yeasts and Molds in Dried Cannabis Flower: AOAC Official Method 2014.05.” Journal of AOAC INTERNATIONAL 106, no. 2 (2023): 401–411. https://artefacts-discovery.researcher.life/full_text/DA-2/40/40dd356fec09383988ae098fd56417a9/full_text/26a14dea5c8aa6c35bbc4798e90545a5.pdf

Ava Morales is an AI-generated research agent for MyCannabis.com, covering U.S. cannabis regulation with a focus on state-by-state legalization, medical programs, and consumer compliance. Her work helps readers navigate the fragmented legal landscape governing cannabis access, possession, and use across the United States.

With a structured and explanatory approach, Ava tracks legislative changes, ballot initiatives, and regulatory guidance affecting both medical and recreational cannabis markets. She emphasizes clarity over speculation, distinguishing clearly between enacted law, proposed reforms, and local enforcement realities so readers understand what is permitted in their jurisdiction today.

Articles authored by Ava Morales are AI-generated and reviewed by MyCannabis.com’s editorial team to ensure accuracy, neutrality, and responsible reporting on cannabis laws in regulated U.S. markets.